Stockscreener 앱 받기
1,064.74
0.02%
-0.26
시장 영업 전:
1067.00
2.26
+0.21%
전일 마감가:
$1,065.00
열려 있는:
$1075
하루 거래량:
2.85M
Relative Volume:
0.93
시가총액:
$949.47B
수익:
$72.25B
순이익/손실:
$25.28B
주가수익비율:
38.33
EPS:
27.781
순현금흐름:
$10.37B
1주 성능:
+4.24%
1개월 성능:
+20.45%
6개월 성능:
-3.59%
1년 성능:
+49.18%
1일 변동 폭
$1,060.36
$1,082.00
1주일 범위
$1,003.69
$1,082.00
52주 변동 폭
$623.78
$1,133.95
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,064.74 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.18 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.12 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.72 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.19 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-16 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 재확인 | BofA Securities | Buy |
| 2025-12-15 | 재확인 | Goldman | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
GC Biopharma Sells U.S. Affiliate Curevo to Eli Lilly for 459.9 Billion Won - Businesskorea
Eli Lilly Set to Acquire Curevo, LimmaTech Biologics, and Vaccine Co. for $4 Billion - scanx.trade
Lilly buys three vaccine firms to target dementia and infection preventionCHOSUNBIZ - Chosunbiz
Micron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next. - The Motley Fool
How The Eli Lilly (LLY) Narrative Is Evolving With GLP-1 Hopes And Obesity Market Doubts - Yahoo Finance
Eli Lilly Buys 3 Vaccine Companies for $3.8B - Powder & Bulk Solids
GC Green Cross Sells U.S. Affiliate Curevo to Eli Lilly - 아시아경제
Former Metro councilman and pastor accused in 'fraud scheme' to steal $200 million from drug company - News Channel 5 Nashville
Lilly spending nearly $4B to acquire three vaccine developers - Inside INdiana Business
Lilly Is Looking for Its Next Act Beyond the Weight-Loss Boom - Barron's
Lilly to acquire three vaccine developers for up to $3.83 billion By Investing.com - Investing.com Canada
Eli Lilly and Company to acquire 3 vaccine development companies for nearly $4 billion - WTHR
Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B - Law360
Eli Lilly acquires three vaccine companies for infectious disease portfolio - Managed Healthcare Executive
Lilly goes on $20 billion buying spree as company seeks next act - The Daily Gazette
What's Going On With Eli Lilly Stock Tuesday?Eli Lilly (NYSE:LLY) - Benzinga
Lilly to buy three vaccine developers for up to $3.8 billion - MSN
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - marketscreener.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Yahoo Finance
Lilly Gets Back Into the Vaccine Business With New Deals - marketscreener.com
LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio - GuruFocus
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms - Proactive financial news
Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive
Lilly dives into vaccine research with 3 biotech buyouts - BioPharma Dive
Eli Lilly spending $3.8 billion to buy vaccine makers - Axios
Healthcare Takeovers Tick Pass $140 Billion After Latest Lilly Spree - Bloomberg.com
Lilly goes on $21B buying spree to build drug pipeline - dailyjournal.net
Lilly to buy three vaccine developers for nearly US$4 billion in infectious disease push - CTV News
Eli Lilly and Co. splashes out $3.8 billion to acquire three companies, aiming to get a head start in the next round of the global vaccine race - 富途牛牛
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - upi.com
Analyst recommendations: Eli Lilly, AutoZone, BP plc, Ferrari, Samsung Electronics… - marketscreener.com
Positive Clinical Data for Eli Lilly's Gene Editing Therapy VERVE-102 - GuruFocus
Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here? - TradingKey
Lilly Expands Into Vaccines With Three Infectious Disease Acquisitions Worth Up to $3.8 Billion - citybiz
Lilly to Acquire Vaccine Company in $1.55 Billion Bet on Epstein-Barr Vaccine Development - citybiz
Lilly to Acquire Curevo in Deal Focused on Next-Generation Shingles Vaccine - citybiz
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Here’s What the Street is Saying About Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly (LLY) Acquires Three Vaccine Firms for Nearly $4 Billi - GuruFocus
Eli Lilly's VERVE-102 Shows Promising Results in Early Trial - GuruFocus
Eli Lilly (LLY) Expands Vaccine Portfolio with $4B in Acquisitio - GuruFocus
Eli Lilly (LLY) Expands Infectious Disease R&D Through New Acqui - GuruFocus
Lilly (LLY) to Acquire LimmaTech Biologics for Up to $780 Millio - GuruFocus
Eli Lilly to acquire Curevo, LimmaTech Biologics and Vaccine Company in multibillion dollar bet on infectious - CNBC TV18
LLY Acquires Vaccine Company Focused on Innovative Nanoparticle Technology - GuruFocus
LLY Expands Vaccine Portfolio with Curevo Acquisition - GuruFocus
Lilly to buy three vaccine developers for up to US$3.8 bil - The Edge Malaysia
Eli Lilly Doubles Down On Vaccines Portfolio; Makes Three Key Acquisitions For Nearly $4 Billion - NDTV Profit
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.78%
0.09%
자본화:
|
볼륨(24시간):